We are live on ! Find out more
SRC

Shufro Rose & Co Portfolio holdings

AUM $1.47B
1-Year Est. Return 19.38%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+19.38%
3 Year Est. Return
+47.49%
5 Year Est. Return
+55.37%
10 Year Est. Return
+200.77%
AUM
$995M
AUM Growth
+$58.3M
Cap. Flow
+$1.53M
Cap. Flow %
0.15%
Top 10 Hldgs %
31.03%
Holding
293
New
25
Increased
75
Reduced
95
Closed
36

Top Buys

Rank Stock Value
1
DD icon
DuPont de Nemours
DD
+$11.7M
2
Y
Alleghany Corp
Y
+$6.27M
3
AON icon
Aon
AON
+$4.05M
4
MTRX icon
Matrix Service
MTRX
+$3.45M
5
SON icon
Sonoco
SON
+$2.78M

Top Sells

Rank Stock Value
1
DD
Du Pont De Nemours E I
DD
+$11.3M
2
AGN
Allergan plc
AGN
+$5.47M
3
COHR icon
Coherent
COHR
+$2.22M
4
MET icon
MetLife
MET
+$2.02M
5
MOS icon
The Mosaic Company
MOS
+$1.83M

Sector Composition

Rank Sector Weight
1 Technology 21.63%
2 Industrials 15.17%
3 Healthcare 14.09%
4 Financials 13.25%
5 Consumer Discretionary 12.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AGG icon
201
iShares Core US Aggregate Bond ETF
AGG
$138B
$369K 0.04%
3,365
ABT icon
202
Abbott
ABT
$180B
$368K 0.04%
6,900
-300
-4% -$15.1K
EFT
203
Eaton Vance Floating-Rate Income Trust
EFT
$283M
-23,700
Closed -$353K
SQM icon
204
Sociedad Química y Minera de Chile
SQM
$19.6B
$362K 0.04%
6,500
AMZN icon
205
Amazon
AMZN
$2.5T
$361K 0.04%
7,500
+1,460
+24% +$71.7K
SNY icon
206
Sanofi
SNY
$104B
$358K 0.04%
7,200
+200
+3% +$9.68K
GSK icon
207
GSK
GSK
$103B
$355K 0.04%
7,000
+1,200
+21% +$60.9K
KMB icon
208
Kimberly-Clark
KMB
$36.4B
$353K 0.04%
3,000
RTX icon
209
RTX Corp
RTX
$287B
$352K 0.04%
4,819
AME icon
210
Ametek
AME
$55.5B
$345K 0.03%
5,224
MHN
211
DELISTED
BlackRock MuniHoldings New Yrok Quality Fund
MHN
-24,500
Closed -$348K
CCRD
212
DELISTED
CoreCard
CCRD
$336K 0.03%
87,867
+9,125
+12% +$36K
FLG
213
Flagstar Bank National Association
FLG
$5.77B
$334K 0.03%
8,633
+1,800
+26% +$67.9K
SABA
214
Saba Capital Income & Opportunities Fund II
SABA
$220M
-25,200
Closed -$337K
ICCC icon
215
ImmuCell
ICCC
$99.8M
$324K 0.03%
49,791
+5,600
+13% +$36.7K
NTRS icon
216
Northern Trust
NTRS
$22.2B
$322K 0.03%
3,500
HSBC.PRA
217
DELISTED
HSBC Holdings PLC, Inc. ADS(1/40 shr. 6.2% Non-Cum. Dlr. Pref. Shrs., Ser.A)
HSBC.PRA
$317K 0.03%
12,025
ELV icon
218
Elevance Health
ELV
$81.9B
$313K 0.03%
1,650
LXP icon
219
LXP Industrial Trust
LXP
$3.53B
$312K 0.03%
6,110
+227
+4% +$11.3K
PSX icon
220
Phillips 66
PSX
$82.9B
$311K 0.03%
3,400
+250
+8% +$21.2K
JEQ
221
DELISTED
abrdn Japan Equity Fund
JEQ
-36,300
Closed -$313K
SWZ
222
Swiss Helvetia Fund
SWZ
$76.3M
-23,921
Closed -$303K
EXC icon
223
Exelon
EXC
$48.6B
$303K 0.03%
11,286
GOOGL icon
224
Alphabet (Google) Class A
GOOGL
$3.91T
$303K 0.03%
6,220
+900
+17% +$42.7K
JPS
225
DELISTED
Nuveen Preferred & Income Securities Fund
JPS
-29,581
Closed -$303K

Similar funds

Shufro Rose & Co's Q3 2017 Portfolio in Review

As of Q3 2017, Shufro Rose & Co held 293 positions worth $995M, up 6.2% from $936M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Shufro Rose & Co's Q3 2017 filing shows 25 new, 75 increased, 95 reduced and 36 closed positions. Its largest new stake was Alleghany Corp: 10,755 shares worth $5.96M. The largest sale was Du Pont De Nemours E I, an estimated $11.3M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 22% a quarter earlier, followed by Industrials and Healthcare.

  • Shufro Rose & Co's largest Q3 2017 buy was Alleghany Corp: 10,755 shares worth $5.96M.
  • Shufro Rose & Co added most to DuPont de Nemours in Q3 2017, an estimated $11.7M increase.
  • Shufro Rose & Co's biggest Q3 2017 reduction was Allergan plc, cutting an estimated $5.47M.
  • Shufro Rose & Co fully exited Du Pont De Nemours E I in Q3 2017, selling an estimated $11.3M.
  • Shufro Rose & Co's ten largest holdings make up 31% of its $995M portfolio in Q3 2017.
  • Shufro Rose & Co opened 25 new positions and closed 36 in Q3 2017.
  • Shufro Rose & Co's portfolio value rose 6.2% quarter-over-quarter to $995M.

Based on Shufro Rose & Co's 13F filing for Q3 2017, filed 13 Nov 2017.